108 related articles for article (PubMed ID: 21463114)
21. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
22. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F; Recher C; Milpied N; Gressin R; Salles G; Brice P; Vey N; Haioun C; Colombat P; Rossi JF; Deconinck E; Lazreg F; Bergougnoux L; Delsol G; Attal M
Ann Oncol; 2012 Oct; 23(10):2687-2695. PubMed ID: 22767588
[TBL] [Abstract][Full Text] [Related]
23. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
[TBL] [Abstract][Full Text] [Related]
24. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Shin HJ; Lee WS; Lee HS; Kim H; Lee GW; Song MK; Kim JS; Yhim HY; Chung JS
Leuk Lymphoma; 2014 Nov; 55(11):2490-6. PubMed ID: 24432893
[TBL] [Abstract][Full Text] [Related]
25. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Tarella C; Zanni M; Di Nicola M; Patti C; Calvi R; Pescarollo A; Zoli V; Fornari A; Novero D; Cabras A; Stella M; Comino A; Remotti D; Ponzoni M; Caracciolo D; Ladetto M; Magni M; Devizzi L; Rosato R; Boccadoro M; Bregni M; Corradini P; Gallamini A; Majolino I; Mirto S; Gianni AM;
Leukemia; 2007 Aug; 21(8):1802-11. PubMed ID: 17554382
[TBL] [Abstract][Full Text] [Related]
26. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.
Blaker YN; Eide MB; Liestøl K; Lauritzsen GF; Kolstad A; Fosså A; Smeland EB; Holte H
Leuk Lymphoma; 2014 Oct; 55(10):2319-27. PubMed ID: 24432894
[TBL] [Abstract][Full Text] [Related]
27. New developments in the management of diffuse large B-cell lymphoma.
Habermann TM
Hematology; 2012 Apr; 17 Suppl 1():S93-7. PubMed ID: 22507791
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients.
Shin HJ; Yoon DH; Lee HS; Oh SY; Yang DH; Kang HJ; Chong SY; Park Y; Do Y; Lim SN; Jo JC; Lee WS; Chung JS;
Exp Hematol; 2016 Jan; 44(1):3-13. PubMed ID: 26325332
[TBL] [Abstract][Full Text] [Related]
29. Is autologous stem cell transplantation for transformed follicular lymphoma still justifiable?
Dickinson M
Leuk Lymphoma; 2012 May; 53(5):754-5. PubMed ID: 22239667
[No Abstract] [Full Text] [Related]
30. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
31. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma.
Zhou X; Wang J; Zhang J; Copley-Merriman C; Torigoe Y; Reyes C; Seymour JF; Offner FC; Trneny M; Salles GA
Hematology; 2015 Apr; 20(3):129-36. PubMed ID: 25029908
[TBL] [Abstract][Full Text] [Related]
32. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
[TBL] [Abstract][Full Text] [Related]
33. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
Arnason JE; Luptakova K; Rosenblatt J; Tzachanis D; Avigan D; Zwicker JI; Levine J; Kim M; Parker JA; Grant B; Joyce RM
Acta Haematol; 2015; 133(4):347-53. PubMed ID: 25677780
[TBL] [Abstract][Full Text] [Related]
34. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
Dilhuydy MS; Lamy T; Foussard C; Gressin R; Casassus P; Deconninck E; Le Maignan C; Damotte D; Milpied N;
Biol Blood Marrow Transplant; 2010 May; 16(5):672-7. PubMed ID: 20045738
[TBL] [Abstract][Full Text] [Related]
35. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
37. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
Gisselbrecht C
Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
[TBL] [Abstract][Full Text] [Related]
38. Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders.
Cerny J; Trneny M; Slavickova A; Pytlik R; Salkova J; Valkova V; Liu Q; Houghton J; Klener P
Hematology; 2009 Aug; 14(4):187-97. PubMed ID: 19635181
[TBL] [Abstract][Full Text] [Related]
39. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
[TBL] [Abstract][Full Text] [Related]
40. Polymyositis following autologous haematopoietic stem cell transplantation.
Hedermann G; Marquart HV; Vissing J
Scand J Rheumatol; 2016 Oct; 45(5):429-31. PubMed ID: 27050436
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
